Also in a real-world setting, new use of SGLT2 inhibitors dapagliflozin, empagliflozin and canagliflozin was associated with a decreased cardiovascular (CV) disease and mortality risk.

In the OSLER-1 and OSLER-2 open-label extension studies, treatment with evolocumab for the duration of 1 year had no apparent effect on glucose homeostasis, but led to a slight weight increase.

Health-related quality of life specific to heart failure was significantly improved with sacubitril/valsartan compared with enalapril in the PARADIGM-HF trial.

Targeting complementary mechanisms of action with bempedoic acid and ezetimibe on top of a statin in hypercholesterolemia, robustly reduced LDL-c levels as well as hsCRP, was safe and well tolerated in a 6-week phase 2 trial.

In the EPIC-Norfolk study and two validation cohorts, 4x4 interquartile comparisons did not show an association of ApoA-I levels with CHD risk within HDL-c quartiles. In contrast, risk was even increased with ApoA-I levels in some quartiles, as were prevalence of CHD risk factors.

In this special communication, it is speculated that SGLT2 inhibitors affect the action of sodium-hydrogen exchangers (NHEs) and thereby sodium levels in kidneys and cardiomyocytes of the heart.

In two large European cohorts, long-term exposure to road traffic noise and ambient air pollution were significantly associated with increased hsCRP, blood glucose and lipids.

A large meta-analysis of nine studies confirmed association of PCSK9 loss-of-function variants with lower LDL-C levels and lower coronary heart disease risk, but not with stroke risk.

The dual GIP/GLP-1 receptor agonist NNC0090-2746 significantly improved glycemic control and reduced body weight, total cholesterol and leptin levels in diabetic patients on metformin.

EBAC-accredited symposium to be held during ESC 2017 in Barcelona, Spain

EBAC-accredited symposium to be held during ESC 2017 in Barcelona, Spain

CME accredited sympsoium to be held during ESC 2017 in Barcelona Spain